Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK negative
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EML4-ALK fusion (27)
ALK fusion (23)
EML4-ALK variant 3 (8)
STRN-ALK fusion (5)
ALK-HIP1 fusion (4)
EML4-ALK L1196M (4)
FN1-ALK fusion (4)
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
EML4-ALK variant 1 (3)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
RANBP2-ALK fusion (3)
SLC8A1-ALK fusion (3)
ALK-EML4_V5 (2)
ALK-HLA-DRB1 fusion (2)
CAD-ALK fusion (2)
CARS1‐ALK fusion (2)
CLTC-ALK fusion (2)
CMTR1-ALK fusion (2)
DCTN1-ALK fusion (2)
EML4-ALK C1156Y (2)
EML4-ALK G1202R (2)
EML4-ALK G1269A (2)
EML4-ALK I1171S (2)
EML4-ALK variant 2 (2)
HIP1-ALK I1171N (2)
KIF5B-ALK fusion (2)
LMO7-ALK fusion (2)
ACVR1-ALK fusion (1)
ALK-DCHS1 fusion (1)
ALK-EML4_V1 (1)
ALK-EML4_V2 (1)
ALK-EML4_V3 (1)
ALK-EML4_V5a (1)
ALK-KIF5B fusion (1)
ALK-LIMS1 fusion (1)
ALK-PPFIBP1 fusion (1)
ALK-ROS1 fusion (1)
CCDC6-ALK fusion (1)
CCDC85A-ALK fusion (1)
CLIP4-ALK fusion (1)
COX7A2L-ALK fusion (1)
CTNND1-ALK fusion (1)
CUX1-ALK fusion (1)
Chr t(2;17)(p23;q23) CLTC/ALK (1)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
EML4-ALK + ALK-PEX13 (1)
EML4-ALK E13;A20 (1)
EML4-ALK F1174C (1)
EML4-ALK I1171T (1)
EML4-ALK S1206Y (1)
EML4-ALK fusion + ALK-FEZ2 fusion (1)
EML4-ALK fusion + ALK-SSH2 fusion (1)
EML4-ALK fusion + ARID2-ALK fusion (1)
EML4-ALK fusion + CDK15-ALK fusion (1)
EML4-ALK variant 3a (1)
EML4-ALK variant 3b (1)
EML4_E13-ALK_E19 fusion (1)
EML4_E20-ALK_E19 fusion (1)
EML4_E6-ALK_E18(V3) (1)
EML6-ALK fusion + FBXO11-ALK fusion (1)
ERC1-ALK fusion (1)
GHR-ALK fusion (1)
HIVEP1-ALK fusion (1)
KANK4-ALK fusion (1)
KIDINS220-ALK fusion (1)
KIF13A-ALK fusion (1)
KLC1-ALK fusion (1)
KLHL31-LRRC1-ALK fusion (1)
LINC01173-ALK fusion + LOC388942-ALK fusion (1)
LOC101927285-ALK fusion (1)
LTBP1-ALK fusion (1)
LTBP1-ALK fusion + HIP1-ALK fusion (1)
LTBP1_E2-ALK_E11 fusion (1)
MPRIP-ALK fusion (1)
MRPS9-ALK fusion (1)
MYH9-ALK + ALK-WDR43 (1)
NBEA-ALK fusion + EML4-ALK fusion (1)
NKAIN2-ALK fusion (1)
NPM-ALK fusion (1)
PRKCB-ALK fusion (1)
PTH2R-ALK fusion (1)
RANBP2-ALK + TMEM217-ALK (1)
SDK1-ALK fusion (1)
SETD2-ALK fusion + EML4-ALK fusion (1)
SPECC1L‑ALK fusion (1)
STRN exon 2-ALK exon 20 fusion (1)
TFG-ALK fusion (1)
TNIP2-ALK fusion (1)
TOGARAM2-ALK fusion (1)
UGP2-ALK fusion (1)
CDK15-ALK fusion (0)
EML6-ALK fusion (0)
FBXO11-ALK fusion (0)
EML4-ALK fusion (27)
ALK fusion (23)
EML4-ALK variant 3 (8)
STRN-ALK fusion (5)
ALK-HIP1 fusion (4)
EML4-ALK L1196M (4)
FN1-ALK fusion (4)
NPM1-ALK F1174C (4)
NPM1-ALK fusion (4)
EML4-ALK variant 1 (3)
NPM1-ALK I1171N (3)
NPM1-ALK I1171T (3)
NPM1-ALK L1196Q (3)
RANBP2-ALK fusion (3)
SLC8A1-ALK fusion (3)
ALK-EML4_V5 (2)
ALK-HLA-DRB1 fusion (2)
CAD-ALK fusion (2)
CARS1‐ALK fusion (2)
CLTC-ALK fusion (2)
CMTR1-ALK fusion (2)
DCTN1-ALK fusion (2)
EML4-ALK C1156Y (2)
EML4-ALK G1202R (2)
EML4-ALK G1269A (2)
EML4-ALK I1171S (2)
EML4-ALK variant 2 (2)
HIP1-ALK I1171N (2)
KIF5B-ALK fusion (2)
LMO7-ALK fusion (2)
ACVR1-ALK fusion (1)
ALK-DCHS1 fusion (1)
ALK-EML4_V1 (1)
ALK-EML4_V2 (1)
ALK-EML4_V3 (1)
ALK-EML4_V5a (1)
ALK-KIF5B fusion (1)
ALK-LIMS1 fusion (1)
ALK-PPFIBP1 fusion (1)
ALK-ROS1 fusion (1)
CCDC6-ALK fusion (1)
CCDC85A-ALK fusion (1)
CLIP4-ALK fusion (1)
COX7A2L-ALK fusion (1)
CTNND1-ALK fusion (1)
CUX1-ALK fusion (1)
Chr t(2;17)(p23;q23) CLTC/ALK (1)
Chr t(2;5)(p23;q35) NPM1/ALK (1)
EML4-ALK + ALK-PEX13 (1)
EML4-ALK E13;A20 (1)
EML4-ALK F1174C (1)
EML4-ALK I1171T (1)
EML4-ALK S1206Y (1)
EML4-ALK fusion + ALK-FEZ2 fusion (1)
EML4-ALK fusion + ALK-SSH2 fusion (1)
EML4-ALK fusion + ARID2-ALK fusion (1)
EML4-ALK fusion + CDK15-ALK fusion (1)
EML4-ALK variant 3a (1)
EML4-ALK variant 3b (1)
EML4_E13-ALK_E19 fusion (1)
EML4_E20-ALK_E19 fusion (1)
EML4_E6-ALK_E18(V3) (1)
EML6-ALK fusion + FBXO11-ALK fusion (1)
ERC1-ALK fusion (1)
GHR-ALK fusion (1)
HIVEP1-ALK fusion (1)
KANK4-ALK fusion (1)
KIDINS220-ALK fusion (1)
KIF13A-ALK fusion (1)
KLC1-ALK fusion (1)
KLHL31-LRRC1-ALK fusion (1)
LINC01173-ALK fusion + LOC388942-ALK fusion (1)
LOC101927285-ALK fusion (1)
LTBP1-ALK fusion (1)
LTBP1-ALK fusion + HIP1-ALK fusion (1)
LTBP1_E2-ALK_E11 fusion (1)
MPRIP-ALK fusion (1)
MRPS9-ALK fusion (1)
MYH9-ALK + ALK-WDR43 (1)
NBEA-ALK fusion + EML4-ALK fusion (1)
NKAIN2-ALK fusion (1)
NPM-ALK fusion (1)
PRKCB-ALK fusion (1)
PTH2R-ALK fusion (1)
RANBP2-ALK + TMEM217-ALK (1)
SDK1-ALK fusion (1)
SETD2-ALK fusion + EML4-ALK fusion (1)
SPECC1L‑ALK fusion (1)
STRN exon 2-ALK exon 20 fusion (1)
TFG-ALK fusion (1)
TNIP2-ALK fusion (1)
TOGARAM2-ALK fusion (1)
UGP2-ALK fusion (1)
CDK15-ALK fusion (0)
EML6-ALK fusion (0)
FBXO11-ALK fusion (0)
›
Associations
(4)
News
Trials
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Search handles
@Tony_Calles
@ixazebe
@ns_chd
@timfenske
Filter by
Latest
1year
ALK-negative anaplastic large cell lymphoma with JAK2 rearrangement mimicking classic Hodgkin lymphoma | Blood | American Society of Hematology https://t.co/r3X6TfGAVp (@ixazebe)
1 year ago
ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
|
ALK negative • JAK2 rearrangement
2years
Great work by @FordePatrick & colleagues. This trial has now established clear role for #immunotherapy in almost all stages of #EGFR/#ALK negative #NSCLC (early-stage neoadjuvant; early-stage adjuvant; locally advanced; metastatic). #PDL1 expression correlated w/ outcomes in all! (@ns_chd)
2 years ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • ALK negative
2years
Based on the recent neo-adjuvant data and approval of Chemo-IO (#CM816) for Stage Ib-IIIA NSCLC, EGFR/ALK negative, what would you be doing in your clinical practice? In neo-adj settings, would you offer: #LCSM @FordePatrick @n8pennell @CharuAggarwalMD @JackWestMD @DrJNaidoo (@OncBrothers)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
ALK negative
2years
Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • ALK negative
almost3years
IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Largest study to date... no impact of DUSP22 rearr on PFS. #16icml https://t.co/JI27UQtgUx (@timfenske)
almost 3 years ago
ALK (Anaplastic lymphoma kinase)
|
ALK negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login